Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Loading NLNK News...
Health Technology » Biotechnology
|GILD||Gilead Sciences, Inc.||0.00%||67.83||1.0%||$594.24m|
|REGN||Regeneron Pharmaceuticals, Inc.||0.00%||369.14||2.1%||$317.75m|
|KITE||Kite Pharma, Inc.||0.00%||76.38||18.8%||$210.13m|
|ALXN||Alexion Pharmaceuticals, Inc.||0.00%||120.08||1.6%||$205.79m|
|ESPR||Esperion Therapeutics, Inc.||0.36%||39.15||18.7%||$165.09m|
|AUPH||Aurinia Pharmaceuticals Inc.||0.00%||8.53||6.3%||$148.77m|
|CLVS||Clovis Oncology, Inc.||0.00%||67.18||17.5%||$141.46m|
|VRTX||Vertex Pharmaceuticals Incorporated||0.00%||90.04||2.2%||$134.96m|
NewLink Genetics Corp. is a biopharmaceutical company, which focuses on discovering, developing and commercializing novel immunotherapeutic products to improve cancer treatment options for patients and physicians. Its portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a range of oncology indications. The company's products include HyperAcute Pancreas, HyperAcute Lung, HyperAcute Melanoma, HyperAcute Imunotherapies, NLG8189 and IDO Pathway Inhibitors. NewLink Genetics was founded by Charles J. Link and Nicholas N. Vahanian on June 4, 1999 and is headquartered in Ames, IA.